NCT05672966

Phase I Clinical Trial of a Candidate HPV Vaccine

A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Wuhan BravoVax Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.

Conditions

• Human Papillomavirus Infection

Interventions

Type	Name	Description
BIOLOGICAL	Human papillomavirus (HPV) Vaccine	0.5mL, Intramuscular
BIOLOGICAL	Placebo	0.5mL, Intramuscular

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-07-31
• Completion: 2024-10-31
• First posted: 2023-01-05
• Last updated: 2023-01-06

Locations

1 site across 1 country: Australia